[Enzyme-chemical aspects of antipsoriatic therapy].
D000818:Animals; D001623:Betamethasone / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use*; D006168:Guinea Pigs; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use*; D010088:Oxidoreductases / Q000378:metabolism; D011239:Prednisolone / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy / Q000201:enzymology*; D014166:Transferases / Q000378:metabolism; D014221:Triamcinolone / Q000627:therapeutic use*
D003879:Dermatologic Agents; D014221:Triamcinolone; D003907:Dexamethasone; D001623:Betamethasone; D011239:Prednisolone; D010088:Oxidoreductases; D014166:Transferases; D006854:Hydrocortisone
Enzymchemische Aspekte der antipsoriatischen Therapie.